Completed PHASE2 INTERVENTIONAL 3-arm NCT02181504

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

Sponsor: Allergan

Interventions abicipar pegol ranibizumab sham procedure

Updated 8 times since 2017 Last updated: Mar 14, 2017 Started: Sep 30, 2014 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Macular Degeneration and is currently completed. Allergan leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chiyoda-ku,Tokyo, Japan , Fukushima, Japan , Kita-ku, Fukuoka-shi Fukuoka, Japan , Kita-ku, Okayama-shi Okayama, Japan , Shinjuku-ku, Japan , Showa-ku, Nagoya-shi Aichi, Japan , Taito Ku Tokyo, Japan , Tennoji-ku Osaka, Japan , Urayasu-shi, Japan , Yamato Kanagawa, Japan and 1 more location